(CLLS) Cellectis S.A. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CLLS) Cellectis S.A. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Cellectis S.A. BCG Matrix is a company-specific strategic tool used to assess the portfolio across Stars, Cash Cows, Question Marks, and Dogs for planning, investment, and portfolio review. What you see on this page is a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
ALLO-316, CD70, Phase 1
ALLO-316 is Cellectis S.A.’s most advanced oncology asset by end-2025: a Phase 1 CD70 CAR-T for clear cell renal cell carcinoma, a setting that makes up about 75% of kidney cancers and still has high unmet need. That gives it the strongest upside in the pipeline. But Phase 1 work is still cash-heavy, so it keeps clinical burn elevated.
ALLO-501A, CD19, lymphoma
ALLO-501A is Cellectis S.A.’s anti-CD19 allogeneic CAR-T for relapsed or refractory B-cell lymphomas. CD19 is still a top cell-therapy target, with five approved CD19 CAR-T products in the U.S. as of 2025, but ALLO-501A remains in a development-heavy phase and has not yet shown commercial scale. Its pool is large, yet it still needs clear clinical and regulatory proof to become a Star.
UCART22, CD22, B-ALL
UCART22 is Cellectis S.A.’s allogeneic CAR-T shot for B-cell acute lymphoblastic leukemia, a high-need market where CD22 remains a validated blood-cancer target. Early clinical interest stays strong because CD22 can help after CD19 failure, and the asset could matter most if response and durability hold in later data. If the program keeps improving on safety and remission depth, it can move from question mark to one of Cellectis S.A.’s strongest stars.
UCART123, CD123, AML
UCART123 fits Cellectis S.A.’s "Question Mark" slot: CD123 in AML is high-value, and AML still drives about 20,800 new U.S. cases and 11,220 deaths a year, with 5-year survival near 32%. The market has heavy trial activity and real need, but UCART123 still needs more capital and clear clinical proof to win share.
- High-value CD123 target
- Large AML unmet need
- Active trial competition
- Proof and funding still needed
TALEN allogeneic CAR-T platform
Cellectis’ TALEN allogeneic CAR-T platform is the core gene-editing engine behind its oncology pipeline, and it can be reused across multiple programs, which keeps development leverage high. In a fast-growing cell-therapy market, that gives Company Name a strong Star profile. The tradeoff is clear: the platform still needs steady R and D funding to move candidates through the clinic.
- Reusable across oncology programs
- High leverage in a growing market
- Needs ongoing R and D spend
Cellectis’ Closest Stars: ALLO-316, UCART22, and TALEN
Cellectis S.A. has no true Stars yet in 2025, but ALLO-316 and UCART22 are the closest: both sit in large, high-need blood or solid-tumor markets and could scale if later data improve. The TALEN platform is the main Star-like asset because it can be reused across programs and supports pipeline breadth. The catch is still clear: all of these remain clinical-stage and need more cash and proof.
| Asset | BCG fit | Key data |
|---|---|---|
| ALLO-316 | Near-Star | Phase 1, ccRCC |
| UCART22 | Near-Star | Early data only |
| TALEN platform | Star-like | Multi-program reuse |
What is included in the product
Detailed Word Document
Cellectis S.A. BCG Matrix analyzes its pipeline across Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.
Editable Excel File
One-page Cellectis S.A. BCG Matrix that quickly spots which units to invest in, hold, or exit.
Reference Sources
Provides a traceable source trail for Cellectis S.A., boosting credibility and helping stakeholders verify assumptions fast.
Cash Cows
Servier collaboration, milestone economics
Servier remains Cellectis S.A.’s closest thing to a cash cow: with no approved drug by FY2025, the company still relied on collaboration fees and milestone payments, not product sales, for recurring cash. That makes the Servier alliance a steadier funding line and a key offset to heavy R&D burn, even if milestone timing stays uneven.
Allogene collaboration, partner-funded programs
Cellectis S.A.’s long-running Allogene Therapeutics tie-up, first signed in 2014, helps fund selected programs and shift R&D spend off Cellectis’ books. The deal can still generate fees and milestone income before any product sales, so it fits a Cash Cow profile even without near-term commercialization.
Cellectis Plants, mature low-growth unit
Cellectis Plants is the mature, lower-growth side of Cellectis S.A., so it fits the Cash Cow slot better than the therapeutic pipeline. It is not the main growth engine; the oncology business drives the upside, while Plants brings steadier, lower-volatility demand. That makes Plants useful for cash support, not for rapid expansion.
French R and D tax credits, non-dilutive funding
French R&D tax credits are a steady, non-dilutive cash source for Cellectis S.A. because the crédit d’impôt recherche can refund up to 30% of eligible French R&D spend. In 2025, that matters more than launch timing: the credit recurs as research spend continues, so it helps fund the pipeline and smooth liquidity.
- Up to 30% of eligible R&D
- Cash support without dilution
- Recur with ongoing research
- Backs pipeline before sales
Platform licensing, process fees
Cellectis S.A. can turn its gene-editing platform into recurring platform licensing and process-fee income, which is steadier than one-off drug pipeline wins. In a pre-commercial biotech, that kind of non-product revenue can act like a cash cow because it helps fund R&D while the new-drug portfolio matures. The point is simple: monetizing know-how can bring in cash before any drug launch.
Recurring, non-dilutive cash support
Slower growth than pipeline upside
Helps fund pre-launch R&D
Cellectis’ Cash Cows: Partner Fees and R&D Tax Credits
Cash Cows for Cellectis S.A. are mostly non-product cash sources: Servier, Allogene Therapeutics, Plants, and French R&D tax credits. In FY2025, these mattered more because Cellectis S.A. still had no approved drug, so recurring fees and refunds helped fund R&D.
| Cash cow | FY2025 cash role |
|---|---|
| Servier | Milestones, fees |
| CIR | Up to 30% of eligible R&D |
What You See Is What You Get
Cellectis S.A. Reference Sources
The Cellectis S.A. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. There are no demo pages or hidden differences—just the full, ready-to-use report. Download it instantly and use it for analysis, presentation, or strategic planning.
Dogs
ALLO-501, earlier CD19 lymphoma asset
ALLO-501 is Cellectis S.A.’s earlier CD19 lymphoma asset, and it sits behind ALLO-501A in the company’s own program ladder. In a CAR-T market with 5 approved CD19 therapies and heavy competition, older assets lose share and strategic pull fast. By end-2025, ALLO-501 fits a low-growth, low-share BCG Dog profile.
ALLO-715, BCMA, legacy multiple myeloma
ALLO-715 sits in a crowded BCMA field, where approved CAR-T and bispecific rivals already dominate multiple myeloma. If Cellectis S.A. has shifted focus away from this legacy asset, its 2025 growth case is weak and the capital return looks poor. In BCG terms, it fits "Dog": low strategic priority, limited upside, and a high chance of tying up scarce cash.
UCART19, first-generation CD19
UCART19 is a first-generation anti-CD19 allogeneic CAR-T, so it sits in Cellectis S.A.’s Dogs bucket. The CD19 field now has multiple approved rivals and far larger clinical datasets, while UCART19 looks more like a legacy asset than a growth engine.
That means its 2025/2026 value is mostly optionality, not revenue power, and it is unlikely to move Cellectis S.A.’s near-term financial profile.
Legacy plant transformation projects
Legacy plant transformation projects at Cellectis S.A. show limited strategic pull versus the oncology pipeline, with mature, slow-moving work that has not shown clear scale. That profile fits the dog quadrant: low growth, weak momentum, and little capital priority.
- Low strategic fit versus oncology
- Mature, slow-growth activity
- Weak case for fresh investment
Paused pipeline slots, sunk R and D
Cellectis S.A. has had several pipeline resets, with some programs delayed or stopped, and that raises the cost of restarting clinical work later. In BCG terms, these are Dogs because they can absorb R&D cash without giving back much near-term value. The drag is real: 2025 filings showed continued net losses and heavy cash use, so paused slots can trap capital instead of funding cleaner shots.
- Delayed programs lose clinical momentum.
- Restart costs rise after a pause.
- R&D can sit with low return.
Cellectis’ Legacy Assets Are Dogs, Not Growth Engines
ALLO-501, ALLO-715, and UCART19 all sit in Cellectis S.A.’s Dogs bucket: older assets in crowded markets, with low growth and weak strategic priority. In 2025/2026, they face heavier rivals in CD19 and BCMA, while Cellectis S.A. still carried net losses and cash burn, so these programs look more like capital drains than value drivers. That is why their BCG role is mostly optionality, not near-term revenue.
| Asset | BCG fit | Key signal |
|---|---|---|
| ALLO-501 | Dog | Legacy CD19 asset |
| ALLO-715 | Dog | Crowded BCMA field |
| UCART19 | Dog | First-gen CD19 CAR-T |
Question Marks
UCARTCS1, CS1, multiple myeloma
UCARTCS1 remains a Question Mark in Cellectis S.A.'s BCG matrix: it is still pre-commercial, with no revenue and high clinical risk. Multiple myeloma is a large target, with more than 188,000 new cases globally in 2022 and a growing CAR-T market, but UCARTCS1 still has negligible share versus approved rivals like Carvykti and Abecma.
Additional solid-tumor CAR-T candidates
Solid tumors are the largest unmet area in oncology, but Cellectis S.A.’s next CAR-T bets beyond ALLO-316 are still early and unproven. The company has no late-stage solid-tumor candidate, so the scale-up case is real but not yet backed by clinical proof or revenue. That makes this a clear Question Mark: high upside, high failure risk.
Next-gen multiplex-edited CAR-Ts
Next-gen multiplex-edited CAR-Ts remain a Question Mark for Cellectis S.A.: the platform is still low-share, with 0 approved products at end-2025. The company keeps refining its editing stack and cell engineering, and better persistence and safety could improve future programs. But these upgrades are still R&D-heavy, so near-term cash use stays high.
AML combination studies, CD123-based
AML combination studies around CD123 are a question mark for Cellectis S.A.: the market is active, but hard to crack. CD123 is present on many AML blasts, and combo trials may widen the addressable pool, but durable response data are still limited, so the route to success is not proven.
- Active AML target, but high trial risk
- Combination use could expand CD123 reach
- Upside exists, yet proof is still thin
New partner-led oncology targets
New partner-led oncology targets stay in Question Mark territory for Cellectis S.A. because future alliances can widen the antigen and indication set, but there is still no proof they can turn into revenue drivers. Partnership-led expansion also spreads R&D risk and keeps cash burn contained while the data package is built.
- Future deals can add new targets.
- Risk stays shared with partners.
- Optionality is preserved until data readouts.
- No clear winner signal yet.
Until clinical data and partner terms are visible, these assets are better treated as optional bets than BCG Stars or Cash Cows.
Cellectis’ Question Marks: High Upside, No Revenue Yet
Cellectis S.A.'s Question Marks are still pre-revenue, high-burn bets: UCARTCS1, solid-tumor CAR-Ts, multiplex-edited programs, and CD123 AML combos. At end-2025, Cellectis S.A. still had 0 approved products, so these assets keep optional upside but no BCG share support yet.
| Asset | Status | BCG read |
|---|---|---|
| UCARTCS1 | Pre-commercial | Question Mark |
| Next-gen CAR-T | 0 approvals at end-2025 | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.